.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK04_Ertugliflozin.Ertugliflozin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK04_Ertugliflozin.Ertugliflozin| name: | Ertugliflozin | |
| ATC code: | A10BK04 | route: | oral |
| compartments: | 2 | |
| dosage: | 15 | mg |
| volume of distribution: | 85.5 | L |
| clearance: | 11.2 | L/h |
| other parameters in model implementation | ||
Ertugliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus to improve glycemic control. It is approved for clinical use and generally administered orally as a tablet.
Pharmacokinetics reported for healthy adult subjects (both sexes), after single and multiple oral doses under fasted and fed conditions.
Li, Y, et al., & Sahasrabudhe, V (2020). Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects. Clinical pharmacology in drug development 9(1) 97–106. DOI:10.1002/cpdd.686 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30934166